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ABSTRACT 
Microfocus synchrotron x-ray fluorescence (SXRF) imaging focussed on detection of 
the Os LIII edge shows that the organo-osmium metallodrug candidate [(ŋ
6
-p-
cym)Os(Azpy-NMe2)I]
+ (p-cym = p-cymene, Azpy-NMe2 = 2-(p-
((dimethylamino]phenylazo)pyridine)) [1] penetrates efficiently into the interior of 
A2780 human ovarian cancer cell spheroids, a model for a solid tumour. The 
accompanying changes in Zn and Ca distribution suggest that the complex causes 
nuclear damage and initiates signalling events for cell death, consistent with findings 
for cultured cancer cell monolayers. Such tumour penetration is likely to be important 
for combatting resistance to chemotherapy, which is becoming a problem for current 
clinical platinum drugs. 
 
Keywords: organometallic metallodrugs, 3D spheroids, tumour penetration, 
elemental mapping, x-ray fluorescence 
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There is a clinical need for new anticancer treatments capable of overcoming 
platinum resistance.1 New generations of drug candidates with novel mechanisms of 
action need to penetrate into the interior of tumours since this is likely to be a major 
factor in determining resistance to chemotherapy.2 Hence, metallodrug candidates 
should be capable of reaching the core of treated tumours.  
Organometallic Ru, Ir and Os-‘piano-stool’ complexes are a class of compounds 
with promising anticancer properties.3-13 In particular, [(ŋ6-p-cym)Os(Azpy-NMe2)I]
+ 
(p-cym = p-cymene, Azpy-NMe2 = 2-(p -((dimethylamino]phenylazo)pyridine)) [1] 
(Chart 1) exhibits potent activity towards a wide range of cancer cell lines. It has a 
different mechanism of action to cisplatin and is capable of overcoming resistance to 
clinical platinum drugs in vitro. It also shows promising antitumour activity in vivo.14, 
15  
 
 
Chart 1. Structure of [(ŋ6-p-cym)Os(Azpy-NMe2)X]
+ [1] and related complexes. 
 
We have demonstrated that 1 is a relatively inert prodrug that can be activated by 
hydrolysis of the Os-I bond under intracellular reductive conditions, generating the 
more reactive Os-OH adduct [1-OH]. Interestingly, the chlorido analogue [1-Cl], 
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behaves similarly to 1, but hydrolyses more rapidly, and is 10x less active in 
inhibiting the proliferation of cancer cells.16 Complex 1 rapidly generates large 
quantities of reactive oxygen species (ROS) inside cells through mitochondrial 
pathways.17, 18 Using synchrotron X-ray fluorescence (SXRF), we showed that 
osmium from 1 is concentrated in small organelles within the cytosol of treated cells, 
possibly mitochondria, leading to extensive nuclear damage, and mobilisation of Ca 
from the endoplasmic reticulum (a signalling event for cell death).19 
The interaction of 1 with solid tumours has yet to be investigated. Here we use 3D 
spheroids as tumour models that can be readily cultured in vitro.20, 21 They provide 
useful systems for the study of tumour growth inhibition and drug penetration. 
Tumour penetration by metallodrugs has been studied by SXRF22-24 and other 
techniques such as Laser Ablation Inductively Coupled Plasma Mass Spectrometry 
(LA-ICP-MS)25 or Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric 
Imaging (MALDI-MSI)26 which allow direct mapping of metals in biological 
samples, including 3D spheroid solid tumour models. 
We have acquired SXRF elemental maps of A2780 human ovarian carcinoma 
spheroids to study the ability of organo-osmium drug candidate 1 to penetrate into 
solid tumours and its effect on the distribution of natural metal ions. 
A2780 ovarian carcinoma 3D spheroids were generated by growing cells for 5 
days in U-bottom cell-repellent 96 well plates. The size of the tumour models was 
controlled by altering the initial cell density. 1000-5000 cells/well yielded spheroids 
with a diameter 4066 m-5608 m; Fig. S1. For tumour growth inhibition assays, 
2500 cells were seeded and grown for 3 days, yielding spheroids of 2756 m 
diameter. They were exposed to 1 for 16 - 48h, and ATP content was measured using a 
luminescence assay to determine cell viability in the 3D spheroids. Cisplatin and 1-Cl 
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(Cl analogue of 1) were studied for comparison. The antiproliferative activity of 
complexes was also determined in monolayer cultures treated with the drugs for the 
same times (Tables 1 and 2, Fig. S2).  
 IC50-sph (M) 
Exposure time 
Complex 16h 24h 48h 
Cisplatin 1919 1088 79.80.2 
1-Cl 864 472 22.30.3 
1 9.70.3 3.50.6 1.430.04 
 
Table 1. Growth inhibition (IC50-sph M) of A2780 human ovarian carcinoma 3D 
spheroid tumour models. 
 
 IC50 (M) 
Exposure time 
Complex 16h 24h 48h 
Cisplatin 9011 23.70.7 150.9 
1-Cl 141 5.50.4 2.00.02 
1 0.80.2 0.50.1 0.100.01 
 
Table 2. Antiproliferative activity (IC50 M) towards monolayers of A2780 human 
ovarian carcinoma cancer cells. 
 
Our experiments show that 1 is highly effective in inhibiting tumour growth, 
being over 50x and 15x times more active than cisplatin and 1-Cl (after 48h 
treatment), respectively. As expected, this pattern is also observed for cell monolayers 
treated with these complexes. Interestingly, increases in the time of exposure of both 
2D and 3D cultured cells to 1 (from 16h to 48h) led to comparable increases in 
antiproliferative activity: 8x and 7x times more active in cell monolayers and 
spheroids, respectively. This was not observed when cells were treated with cisplatin 
or 1-Cl; longer exposure times led to dramatically higher improvements in the 
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biological activity of cisplatin and 1-Cl in cell monolayers compared to 3D spheroids 
(Fig. S3). Overall, this suggests that 1 penetrates into spheroids in an efficient time-
dependent way. To investigate whether this, microfocus x-ray fluorescence imaging 
experiments were carried out to map the distribution of osmium in the spheroids. 
Synchrotron x-ray fluorescence (SXRF) was used to study the tumour spheroid 
penetration properties of osmium from complex 1 in A2870 spheroids treated with 0.7 
µM 1 (½ IC50-sph) for 0, 16, 24 and 48h. Cells were fixed with glutaraldehyde, 
dehydrated with ethanol and embedded in resin for ultramicrotomy. Chemical fixation 
is not ideal for the preservation of biologically relevant elements in adherent 
mammalian cells,27 but it is required to produce thin sections for elemental analysis of 
spheroids and tissues. Elemental maps of 500 nm thick sections of each sample were 
acquired on beamline I18 (DIAMOND Light Source, UK).28 The beam was focused 
to a 2x2 m2 size, and energy fixed at 12 keV to achieve excitation of the Os LIII-
edge. The presence of Os in samples treated with 1 was confirmed by detection of the 
Os LIII X-ray fluorescence emission lines (Fig. S4).  
Interestingly, the results suggest that 1 penetrates into the tumour core, and 
remains there for longer than expected. Although the background contribution could 
not be totally eliminated by peak fitting, maps of 300x300 m2 areas of interest 
(ROIs) collected from the different samples (step size 2x2 µm2, dwell time 1 s; Fig. 1, 
Fig. S5-S8) showed that there is a direct relation between cell treatment time and 
tissue penetration of the complex (Fig. 1-2, Fig. S6). 1 occupies similar areas of the 
spheroids after 24h and 48h treatment. About 18% of the area studied contained Os, 
Fig. S9. However, Os penetrates more deeply into the tumour model (Fig. 2), and is 
accumulated more after 48 h > 24 h > 16 h, with levels of 6.41.6 > 4.80.7 > 
0.110.02 pg Os/section respectively (Fig. S10). In contrast, cell monolayers showed 
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maximum uptake of 1 after 24h incubation, followed by a rapid decrease in the 
amount of Os inside cells during the next 48 h.29 Differences in the accumulation 
kinetics of 1 between cell monolayers and 3D tumour models may result from more 
effective efflux from cell monolayers, or slow diffusion of the drug into tissue-like 
samples.  
 
Fig. 1. Bright field images and SXRF elemental maps of Os, Ca and Zn in A2780 
human ovarian carcinoma spheroid sections (500 nm thick) treated with 0.7 µM 1 (½ 
IC50) for 0, 16, 24 or 48 h. Raster scan: 2x2 µm2 step size, 1 s dwell time. Scale bar 
100 µm. Calibration bar in ng mm-2. Yellow squares in bright field images indicate 
areas of the spheroid studied using SXRF. Red areas in SXRF elemental maps 
indicate the limits of the spheroids. 
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Fig 2. Average Os content (in ng mm-2) as a function of distance from A2780 3D 
spheroid surface, after treatment for 16 h (purple), 24 h (red) or 48 h (green) with 0.7 
µM 1. 
 
The correlation between incubation time and amount of Os at the core of the 
spheroids, suggests that 1 is internalised by transcellular transport mechanisms. This 
means that the drug would be taken up by cells at the surface of the tumour and then 
moves towards more internal areas, being activated in the process. To investigate this, 
X-ray Absorption Spectroscopy (XAS) spectra were collected in areas with relatively 
high concentrations of Os within different parts of the spheroids. Well defined X-ray 
Absorption Near Edge Structure (XANES) and weak Extended X-Ray Absorption 
Fine Structure (EXAFS) for Os were observed (Fig 3). However, S/N ratio was too 
low, most likely due to the low concentration of Os in the sample, and did not allow 
the meaningful fitting of the spectra. Attempts to use longer or multiple acquisitions to 
increase the S/N ratio led to a rapid decrease in the intensity of the XAS spectra, even 
when attenuators were used. This is likely to be due to beam damage of the sample, 
and hampered use of XAS to study the cellular speciation of 1. 
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Fig 3. XAS spectra of Os (A) in A2780 3D spheroids treated for 48 h with 0.7 µM 1, 
and (B) complex 1 as a cellulose pellet. 
 
Treatment of spheroids with 1 also led to extensive changes in Zn and Ca 
distribution, from being discretely localised in untreated samples to being more 
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widely distributed in treated spheroids (Fig. 1, Fig. S7-S8). This change in distribution 
was time-dependent. After 16h exposure to the drug, some Zn and Ca are still 
discretely localised in certain areas of the spheroids, whereas after 24 or 48h 
incubation, they are more evenly distributed. This is probably not the result of an 
increase in metal leaching from spheroids during sample preparation, as the total 
amount of Zn remained mostly unchanged across the different samples, while the 
quantity of Ca found in the sections increased after spheroids were treated with 1 (Fig. 
S10). The changes observed in the Zn and Ca maps of spheroids are in good 
agreement with those observed for monolayer cultured cells treated with the drug. 
Overall, these alterations suggest the presence of nuclear damage with Ca release 
from the endoplasmic reticulum (ER), possibly indicating programmed cell death. The 
presence of abnormally high sub-G0 populations in cell cycle studies is consistent 
with this.  However, no mitochondrial loading with Ca is observed, suggesting that 1 
does not induce apoptosis, and the mechanism of cell death remains to be further 
eliucidated.19 
Our microfocus x-ray fluorescence experiments on Diamond synchrotron 
beamline I18 have provided new insights into the interaction of organo-osmium drug 
candidate 1 with solid tumours. The SXRF maps show that the Os drug penetrates 
efficiently into tumour spheroids, although more complicated models would be 
required to mimic the heterogeneous nature of solid tumours. Complex 1 is more 
effective than cisplatin in inhibiting tumour growth in vitro, and it has a different 
mechanism of action in cells compared to current platinum drugs. Our results 
highlight the potential of 1 as a candidate for further development as a clinical drug to 
treat platinum resistant tumours, a current clinical need. 
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Abbreviations 
SXRF  Synchrotron x-ray fluorescence; 
p-cym  p-cymene; 
Azpy-NMe2 2-(p-((dimethylamino]phenylazo)pyridine);  
ROS  Reactive Oxygen Species; 
LA-ICP-MS Laser Ablation Inductively Coupled Plasma Mass Spectrometry;  
MALDI-MSI Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric 
Imaging; 
IC50-sph  50% inhibition concentrations for 3D spheroids;  
IC50  50% inhibition concentrations; 
ROIs  Areas of interest; 
ER  Endoplasmic Reticulum; 
XAS  X-ray Absorption Spectroscopy; 
XANES X-ray Absorption Near Edge Structure; 
EXAFS Extended X-Ray Absorption Fine Structure. 
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Graphical abstract 
 
 
 
Synopsis: Microfocus synchrotron x-ray fluorescence imaging reveals efficient 
penetration of an organo-osmium anticancer complex into the interior of tumour 
models, leading to cellular changes which suggest nuclear damage and initiation 
of cell death events. 
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Highlights 
 
 Organo-osmium drug candidate efficiently inhibits tumour proliferation in 
vitro  
  
 Synchrotron x-ray fluorescence (SXRF) can map metal distribution in tumours 
 
 SXRF maps show that our Os drug penetrates efficiently into A2780 tumour 
spheroids  
 
 Os drug penetrates into tumours and is accumulated in a time-dependent 
manner  
 
 Zn and Ca maps suggest nuclear damage and initiation of a cell death process  
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